Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12081
Sealed predictions
- NBEAL2 in dopamine neurons, braak-0.45 (p 0.227) → -0.59 (p 0.092)receipt 12089
Swarm cases
receipt 12089: NBEAL2 in dopamine neurons, braak
- power
- full sample -0.57 (p 0.013, n 18), 95% CI -0.82 to -0.14. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.59 (p 0.0092, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.71 (p 9.6e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.69 to -0.52, sign flips 0; without severely affected donors -0.57 (p 0.013, n 18). robust.
- cell type
- strongest in microglia: -0.63 (p 0.0055, n 18) vs -0.57 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NBEAL2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NBEAL2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.22 p 0.424 (needs p < 1.8e-4)
Receipts
loading the receipts